Sign up to read this article for FREE!
After signing up, you'll start to receive regular news updates from us.
GlycoMimetics Awarded NIH Grant to Study Drug Candidate in Diabetes
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
GlycoMimetics, Inc. has announced it has been awarded a grant from The National Heart, Lung, and Blood Institute (NHLBI) of The National Institutes of Health (NIH) to evaluate its E-selectin small molecule antagonists in animal models of vascular complications of diabetes.
The grant is based upon substantial data in the scientific literature suggesting an important role for E-selectin in the chronic inflammation associated with diabetes. The company has developed a family of potent small molecule E-selectin antagonists which it is currently optimizing for oral availability.
“We are excited about the potential for our E-selectin antagonists to treat or prevent vascular complications of diabetes, and we believe GlycoMimetics’ family of small molecule therapeutics could represent a breakthrough in this field,” said John Magnani, Ph.D., GlycoMimetics’ Vice President and Chief Scientific Officer. “It is gratifying to have this important research recognized by the NIH.”
Elevated levels of E-selectin have been shown to correlate with increased risk of complications related to poor microvascular blood flow, such as diabetic retinopathy and nephropathy. GlycoMimetics has discovered a class of potent E-selectin inhibitors, one of which, in earlier tests, was shown to improve blood flow by inhibiting leukocyte rolling and adhesion in diabetic mice.
The company believes that E-selectin antagonists could also be beneficial in treating certain inflammatory skin conditions where E-selectin plays an important role.
The grant is based upon substantial data in the scientific literature suggesting an important role for E-selectin in the chronic inflammation associated with diabetes. The company has developed a family of potent small molecule E-selectin antagonists which it is currently optimizing for oral availability.
“We are excited about the potential for our E-selectin antagonists to treat or prevent vascular complications of diabetes, and we believe GlycoMimetics’ family of small molecule therapeutics could represent a breakthrough in this field,” said John Magnani, Ph.D., GlycoMimetics’ Vice President and Chief Scientific Officer. “It is gratifying to have this important research recognized by the NIH.”
Elevated levels of E-selectin have been shown to correlate with increased risk of complications related to poor microvascular blood flow, such as diabetic retinopathy and nephropathy. GlycoMimetics has discovered a class of potent E-selectin inhibitors, one of which, in earlier tests, was shown to improve blood flow by inhibiting leukocyte rolling and adhesion in diabetic mice.
The company believes that E-selectin antagonists could also be beneficial in treating certain inflammatory skin conditions where E-selectin plays an important role.
